India, July 13 -- Cadrenal Therapeutics (CVKD), a late-stage biopharmaceutical company, on Monday announced late-breaking data from the Phase 2 study for CAD-1005 in treating Heparin Induced Thrombocytopenia. The data was presented at the International Society on Thrombosis and Hemostasis (ISTH) 2026 congress.
CAD-1005 is a novel, selective, 12-lipoxygenase (12LOX) inhibitor that acts by blocking the immune signaling loop that drives antibody-mediated platelet activation. The drug was developed for the treatment of patients with heparin induced thrombocytopenia (HIT).
CAD-1005 was granted Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA) and Orphan Drug status from the European Medicines Agency (EMA)...